TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06562803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double plasma cytokine adsorption system with sequential low-dose plasma exchange
Description: Both groups received comprehensive medical treatment, including antiviral therapy for hepatitis B, anti-infection treatment, supportive care, symptomatic treatment, and prevention of complications. Artificial liver therapy was initiated for both groups on the day of enrollment, with treatments administered every other day for a total of two sessions.~The experimental group underwent treatment with the double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE). This involved using a cytokine adsorption column (CA280,Jafron Biomedical Co., Ltd., Zhuhai, China) and a bilirubin adsorption device (BS330,Jafron Biomedical Co., Ltd., Zhuhai, China) on the same treatment circuit. DPCAS treatment was performed first, with an adsorption volume of 4500ml to 5000ml over 2 to 3 hours, followed by plasma exchange (PE), with 1000ml of plasma and 500ml of 4% albumin being infused.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasma exchange
Description: Based on comprehensive medical treatment, the control group received plasma exchange(PE) treatment, where whole blood was processed through a plasma separator (MICROPLAS MPS 07, BELLCO S.R.L., Italy), with a portion of the plasma discarded and replaced with 1000ml of plasma and 500ml of 4% albumin.
Study: NCT05635851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate Only Product in Oromucosal Dose Form
Description: Glyceryl trinitrate will be administered via sublingual spray.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sublingual spray
Description: A placebo sublingual spray will be administered.
Study: NCT06500780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching and Decision Aid
Description: Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
Study: NCT05909735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of a Descemet's Membrane corneal onlay, partial LSCD
Description: The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity and improvement in limbal stem cell deficiency, and monitored for adverse events.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of a Descemet's Membrane corneal onlay, total/near-total LSCD
Description: The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane (DM) corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity, limbal stem cell deficiency, and persistent epithelial defects/recurrent erosions, and monitored for adverse events.
Study: NCT05630092

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Maximal 6-minute Walk Test (Max_6MWT)
Description: Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Maximal 6-minute Walk Test (Max_6MWT)
Description: Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Normal speed 6-minute Walk Test (Nor_6MWT)
Description: Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Normal speed 6-minute Walk Test (Nor_6MWT)
Description: Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
Study: NCT05942053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo match vitamin K2 capsules once per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K 2
Description: Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
Study: NCT05948579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention B Vilazodone Hydrochloride (HCl)
Description: Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intervention B Placebo
Description: A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
Study: NCT06575894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Facilitation
Description: Home visiting supervisor trained in adapted facilitation will employ interactive problem-solving focused on supporting the home visitors to implement Mothers and Babies - working with pregnant people, challenges with resources, additional training needs, etc. - based on understanding the individual communities, contexts, and recipients' and home visitors' needs over the course of the project.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implementation
Description: Standard Mothers and Babies training includes ongoing implementation support from the Mothers and Babies training team
Study: NCT05919043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb-based movement priming (UL-priming)
Description: Repetitive upper limb movements administered to the beat of a metronome.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower limb-based movement priming (LL-priming)
Description: Repetitive lower limb movements administered to the beat of a metronome.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham priming
Description: Auditory stimulation.
Study: NCT05388695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
Description: Single or sequential injection of CD19, CD20 and CD22 CAR T cells.
Study: NCT05473897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catalyst Cryohelmet
Description: The Catalyst Cryohelmet will be used to provide head and neck cooling. It comes in three sizes based on head circumference. Once informed consent is obtained then the patient's head will be measured to provide the correct helmet size. The Cold Packs will be stored in the emergency department freezer and applied to the helmet once the helmet is ready to be applied. The Cryohelmet will be washed between uses. The Catalyst Cryohelmet is registered with the FDA as D344812. It is a Class I (minimal risk) device not requiring pre-marketing or regulatory processes.
Study: NCT06492304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX131
Description: CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
Study: NCT05804942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High glycemic index
Description: Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:\>70), 20% fat and 20% protein.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium glycemic index
Description: Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:55-70), 20% fat and 20% protein.
Study: NCT05595720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hight intenisty laser
Description: 7W(LAZR-207)/15W(LAZR-215\&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
Study: NCT05198453

Intervention type: BIOLOGICAL
Intervention: vaccination
Description: patients who received COVID-19 vaccine
Study: NCT05804942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low glycemic index
Description: Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:\<55), 20% fat and 20% protein.
Study: NCT05592652

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Survey including demographic, clinical and psychopathological questions

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Survey including demographic, clinical and psychopathological questions

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Survey including demographic, clinical and psychopathological questions

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Survey including demographic, clinical and psychopathological questions
Study: NCT05588674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: 8.5 week supplementation period. One capsule daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: 8.5 week supplementation period. One capsule daily.
Study: NCT04518553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active comarator using antiviral drug of nucleoside analogues
Description: using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA+purification
Description: Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.
Study: NCT05735028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centipeda minima+PD-1/PD-L1 inhibitor
Description: Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1/PD-L1 inhibitor
Description: PD-1/PD-L1 inhibitor
Study: NCT04729101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Oral capsule
Study: NCT05327439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine (electronic cigarette)
Description: Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at in-person and phone assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose one of two e-liquid flavors (tobacco, menthol) at baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine (nicotine pouch)
Description: Participants will be provided with 4mg nicotine pouches for 8 weeks and encouraged at in-person and phone assessments to use the nicotine pouches any time they would normally smoke. Participants will be able to choose one of two nicotine pouch flavors (tobacco, mint) at baseline.
Study: NCT06426082

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Thermoneutral condition
Description: Participants will be exposed 2 hours/day at 32ºC for 5 days/week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold condition
Description: Participants will be exposed 2 hours/day at 18ºC for 5 days/week
Study: NCT05935514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW Intervention
Description: The core of the WW food program is the Points® system which assigns each food and beverage a Points® value. Participants will be assigned a personalized daily and weekly Points® Budget, based on reported goals, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure. Participants will also be provided with the FreeStyle Libre 2 Flash Glucose Monitoring System, which is intended to monitor interstitial fluid glucose levels to aid users in the management of diabetes. The System consists of the following primary components: 1) A disposable sensor that incorporates a subcutaneously implanted electrochemical glucose sensor and associated on-body electronics, and 2) A disposable, sensor application device, which is used to adhere the sensor to the skin of the user and to insert the sensor tail just below the surface of the skin.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The Usual Care arm will continue to receive routine medical care by their provider, in addition to a 50-minute virtual, on-line session with a Registered Dietician, with additional materials at the time of their 6- and 12-month follow-up assessments.
Study: NCT05430022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism-adapted Group Cognitive Behavioral Therapy
Description: The autism-adapted Group Cognitive Behavioral Therapy (CBT) was designed by the PI and research team in collaboration with autistic stakeholders (i.e., adults, parents, researchers). It is a 12-week group intervention (90 min) delivered on a weekly basis in an outpatient psychiatry clinic by licensed clinical psychologists and psychology trainees. Each group is comprised of 8-9 autistic adolescents (11-17 years old; middle and high school) with depression. The intervention targets adolescents' perception and understanding of self, including autistic identity, through a series of cognitive-behavioral approaches including psychoeducation, emotion regulation, cognitive distortions, cognitive restructuring, behavioral rehearsals, and weekly homework assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism-adapted Group Cognitive Behavioral Therapy
Description: The autism-adapted Group Cognitive Behavioral Therapy (CBT) was designed by the PI and research team in collaboration with autistic stakeholders (i.e., adults, parents, researchers). It is a 12-week group intervention (90 min) delivered on a weekly basis in an outpatient psychiatry clinic by licensed clinical psychologists and psychology trainees. Each group is comprised of 8-9 autistic adolescents (11-17 years old; middle and high school) with depression. The intervention targets adolescents' perception and understanding of self, including autistic identity, through a series of cognitive-behavioral approaches including psychoeducation, emotion regulation, cognitive distortions, cognitive restructuring, behavioral rehearsals, and weekly homework assignments.
Study: NCT05400122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: Vactosertib is a highly selective, potent inhibitor of the protein serine/threonine kinase activity of transforming growth factor (TGF)-β receptor type 1 (TGFBR1; also known as activin receptor-like kinase 5 \[ALK5\]). Vactosertib inhibits the phosphorylation of the ALK5 substrates Smad2 and Smad3, as well as the intracellular signaling of TGF-β.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoroara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity.
Study: NCT06245655

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: TENS 7000 digital TENS unit, a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: TENS 7000 digital TENS unit, a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
Study: NCT06190379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential oil blend
Description: an aroma stick containing a blend of essential oils

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an aroma stick containing an inert blend of oils
Study: NCT06326541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Listening to the Holy Quran.
Study: NCT05905198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programming
Description: programming the implanted DBS device to adjust the parameter and switch stimulation mode between Variable-Frequency settings and High-Frequency settings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programming
Description: programming the implanted DBS device to adjust the parameter and switch stimulation mode between Variable-Frequency settings and High-Frequency settings.
Study: NCT06068192

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06365346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic video-assisted gamified group-based music breathing therapy
Description: Dyadic video-assisted gamified music breathing therapy comprising six 75-min weekly sessions delivered in a group size of 6-8 (first sessions: parents only; reminding 5 sessions: parent-child dyads).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online educational modules
Description: Six weekly educational modules on ADHD and its management via email.
Study: NCT04816721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension to match EDP-938
Study: NCT05400122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Proleukin® (aldesleukin) has been shown to possess the biological activities of human native interleukin-2. In vitro studies performed on human cell lines demonstrate the immunoregulatory properties of Proleukin, including: a) enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines; b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.~The in vivo administration of Proleukin in animals and humans produces multiple immunological effects in a dose dependent manner. These effects include activation of cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and the production of cytokines including tumor necrosis factor, IL-1 and gamma interferon. In vivo experiments in murine tumor models have shown inhibition of tumor growth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Killer Cells
Description: Adoptive NK cell therapy has demonstrated the potential for cancer immunotherapy in various malignancies with particular potential in hematologic malignancies including acute myeloid leukemia (AML), and colon cancer \[14, 19-23\]. This therapeutic approach is extremely well tolerated in patients even when massive numbers of cells are utilized (\~109 NK cells/kg). In fact, studies suggest that high doses of NK cells are not only well tolerated but have potential to lead to higher levels of efficacy.
Study: NCT06438562

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unfortified bouillon plus vitamin A in oil
Description: Participants consume unfortified bouillon with vitamin A oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with vitamin A #1 plus unfortified oil
Description: Participants consume vitamin A #1 fortified bouillon plus unfortified oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with vitamin A #2 plus unfortified oil
Description: Participants consume vitamin A #2 fortified bouillon plus unfortified oil
Study: NCT06414408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Pill
Description: 200mg Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Pill
Description: 200mg Dose
Study: NCT06426082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise condition
Description: Participants will perform aerobic exercise training 5 days/week at 65% heart rate reserve for 60 minutes each training session
Study: NCT04098666

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablet identical to metformin, up to 4 tablets a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release metformin
Description: Metformin extended release 500 mg tablets, up to 4 tablets a day
Study: NCT06252636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A2 Milk
Description: Cow's milk that contains only A2 β-Casein.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A1/A2 Milk
Description: Cow's milk that contains both A1 β-Casein and A2 β-Casein.
Study: NCT05230459

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AB-1003 dose level 1
Description: Single intravenous infusion of AB-1003 gene therapy at dose level 1

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AB-1003 dose level 2
Description: Single intravenous infusion of AB-1003 gene therapy at dose level 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous infusion of Placebo
Study: NCT06426082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Participants will take salbutamol 12 mg/day. 7 days week